Fresenius-licensed Endexo Smart Polymer Gets FDA Breakthrough Status to Prevent Clots
nterface Biologics Inc. (IBI) from Canada has developed Endexo as a way to help make dialyzer membranes and bloodlines more biocompatible—and less likely to clot. The technology, for which Fresenius holds an exclusive world-wide license, will reduce the need for heparin and other blood thinners.
Read the full article » | Posted 11-16-2019
Related Articles
- Global Wearable Artificial Kidney Market Expected to Grow Posted 07-12-2024
- Byonyks X1: a New, Small, Portable APD Machine Posted 06-14-2024
- The Public-Private ASN, DHSS, KidneyX Partnership is 5 Years Old This Year Posted 05-09-2024
- New Measure of Home Dialysis Dropout Posted 01-16-2024